[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100387296":3},{"organization":4,"armGroups":7,"interventions":42,"overallOfficials":75,"centralContacts":80,"locations":90,"responsibleParty":106,"collaborators":108,"id":109,"slug":108,"hasResults":110,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":110,"sex":116,"minAge":117,"maxAge":108,"enrollmentInfo":118,"targetDuration":108,"studyType":121,"phases":122,"briefSummary":124,"conditions":125,"keywords":108,"overallStatus":93,"whyStopped":108,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},{"fullName":5,"class":6},"Hunan Province Tumor Hospital","OTHER",[8,14,19,24,29,34,38],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort A: EGFR mutation","EXPERIMENTAL","Lung Cancer with EGFR mutation including EGFR exon19del, exon 21L858R, etc.",[13],"Drug: Osimertinib",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort B: ALK fusion","Lung Cancer with ALK fusion.",[18],"Drug: Alectinib 150 MG",{"label":20,"type":10,"description":21,"interventionNames":22},"Cohort C: ROS1 fusion","Lung Cancer with ROS1 fusion.",[23],"Drug: Crizotinib 250 MG",{"label":25,"type":10,"description":26,"interventionNames":27},"Cohort D: MET alterations","Lung Cancer with MET alteration including amplification, exon 14 skipping and met fusion etc.",[28],"Drug: Savolitinib, Crizotinib.",{"label":30,"type":10,"description":31,"interventionNames":32},"Cohort E: RET fusion","Lung Cancer with RET fusion.",[33],"Drug: Chemotherapy",{"label":35,"type":10,"description":36,"interventionNames":37},"Cohort F: KRAS mutation","Lung Cancer with KRAS mutation.",[33],{"label":39,"type":10,"description":40,"interventionNames":41},"Cohort G: uncommon mutation","Cohort G mainly includes all identified lung cancer mutations except EGFR mut, ALK fusion, ROS1 fusion, MET alterations, KRAS mut and RET fusion. These include: BRAF V600E and non-V600E, NRG fusion, NTRK fusion, ERBB2 amp and mut，NRAS mut, MAP2K1 mut，RIT1 mut, RAF1 mut, FGFR fusion, ARAF mut, HRAS mut etc.",[33],[43,50,56,62,68],{"type":44,"name":45,"description":46,"armGroupLabels":47,"otherNames":48},"DRUG","Osimertinib","Osimertinib 80mg, po, qd;",[9],[49],"Erlotinib, Gefitinib, Furmonertinib, Almonertinib etc.",{"type":44,"name":51,"description":52,"armGroupLabels":53,"otherNames":54},"Alectinib 150 MG","Alectinib 600mg, po, qd; Lorlatinib, 100mg, po, qd;",[15],[55],"Lorlatinib, Alectinib, Brigatinib, Ceritinib etc.",{"type":44,"name":57,"description":58,"armGroupLabels":59,"otherNames":60},"Crizotinib 250 MG","Crizotinib 250 MG po bid.",[20],[61],"Entrectinib",{"type":44,"name":63,"description":64,"armGroupLabels":65,"otherNames":66},"Savolitinib, Crizotinib.","Savolitinib, 300mg po qd.",[25],[67],"Crizotinib",{"type":44,"name":69,"description":70,"armGroupLabels":71,"otherNames":72},"Chemotherapy","500mg, ivgtt, every 21day.",[30,35,39],[73,74],"Pemetrexed, Cisplatin","Pralsetinib etc.",[76],{"name":77,"affiliation":78,"role":79},"Yongchang Zhang, MD","Hunan Cancer Hospital","PRINCIPAL_INVESTIGATOR",[81,86],{"name":77,"role":82,"phone":83,"phoneExt":84,"email":85},"CONTACT","+8613873123436","7+861383123436","zhangyongchang@csu.edu.cn",{"name":87,"role":82,"phone":88,"phoneExt":83,"email":89},"Nong Yang, MD","+8613055193557","yangnong0217@163.com",[91],{"facility":92,"status":93,"city":94,"state":95,"zip":96,"country":97,"cosmosGeoPoint":98,"geoPoint":103,"contacts":104},"Yongchang Zhang","RECRUITING","Changsha","Hunan","410013","China",{"type":99,"coordinates":100},"Point",[101,102],112.97087,28.19874,{"lat":102,"lon":101},[105],{"name":77,"role":82,"phone":83,"phoneExt":83,"email":85},{"type":79,"investigatorFullName":92,"investigatorTitle":107,"investigatorAffiliation":5,"oldNameTitle":108,"oldOrganization":108},"Professor, Director of Clinical Trial Center",null,"100387296",false,"NCT04322890","Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.","PIKACHU","Inclusion Criteria:\n\n1. Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.\n2. Age ≥ 18 years.\n3. Histologically or cytologically confirmed, Stage IV NSCLC.\n4. Oncogenic mutations confirmed by an accredited local laboratory, including EGFR, ALK, ROS1 etc.\n5. ECOG 0-1.\n6. Predicted survival ≥ 12 weeks.\n7. Adequate bone marrow hematopoiesis and organ function\n8. Presence of measurable lesions according to RECIST 1.1.\n\nExclusion Criteria:\n\nThe patient did not match from the Inclusion Criteria.","ALL","18 Years",{"count":119,"type":120},6000,"ESTIMATED","INTERVENTIONAL",[123],"PHASE2","The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.",[126,127,128,129,130],"Non Small Cell Lung Cancer","EGFR Gene Mutation","ALK Gene Mutation","ROS1 Gene Mutation","MET Gene Mutation","2024-10-19",{"date":133,"type":134},"2024-10-22","ACTUAL",{"date":136,"type":134},"2020-04-16",{"date":138,"type":120},"2027-12-24",{"name":5,"class":6},1]